-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
Shares of AVTR jumped in premarket trading as Q1 results topped estimates despite underlying weakness, with adjusted EPS of $0.17 beating consensus by $0.01 though down from $0.23 in the prior year. Net sales remained flat at $1,581.4M but organic revenue declined 4.1%, with both VWR Distribution & Services (-4.8%) and Bioscience & Medtech Products (-2.0%) experiencing organic declines. Management characterized VWR's performance as showing "stabilization" after prolonged weakness. The higher-margin Bioscience segment (23.8% adjusted operating margin vs VWR's 9.2%) demonstrated "improved execution" and represents a key focus for Revival transformation efforts, in our view. Profitability metrics showed significant compression, with adjusted EBITDA margin falling 310 basis points to 13.9%. Operating cash flow declined to $58.7M from $109.3M, indicating continued working capital pressures. AVTR reaffirmed full-year 2026 guidance, suggesting management confidence despite the challenging environment.